Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the regenerative medicine contract services business, recognition of revenue from some projects was deferred due to circumstances affecting customers and other factors, and revenue is expected to decline. Meanwhile, company-wide expense reductions were implemented thoroughly, and operating income is expected to remain in line with the previous forecast, while ordinary loss and net loss are expected to narrow.
| Item | Details |
|---|---|
| Net Sales | 71 Millions of yen → 50 Millions of yen（-29.6%） |
| Operating profit | -1,225 Millions of yen → -1,225 Millions of yen |
| Ordinary income | -1,250 Millions of yen → -1,234 Millions of yen |
| Profit attributable to owners of the parent | -1,320 Millions of yen → -1,309 Millions of yen |
| Net income per share | -30.51 Yen → -33.81 Yen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Fiscal year ended December 2025: net sales: ¥83 million; operating loss: △¥1,046 million; ordinary loss: △¥1,051 million; net loss: △¥1,104 million; net loss per share: △¥31.82 |
| Reason for the revision | In the regenerative medicine contract services business, recognition of revenue from some projects was deferred due to circumstances affecting customers and other factors, and revenue is expected to decline. Meanwhile, company-wide expense reductions were implemented thoroughly, and operating income is expected to remain in line with the previous forecast, while ordinary loss and net loss are expected to narrow. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the regenerative medicine contract services business, the company expects revenue to decline because recognition of revenue from some projects was deferred due to circumstances affecting customers and other factors. Although the decline in revenue will weigh on profit, the company expects operating income to remain unchanged and ordinary loss and net loss to narrow because it has implemented company-wide expense reductions.